PL3498281T3 - Podstawiona pochodna policyklicznego pirydonu i kompozycja farmaceutyczna zawierająca jej prolek - Google Patents

Podstawiona pochodna policyklicznego pirydonu i kompozycja farmaceutyczna zawierająca jej prolek

Info

Publication number
PL3498281T3
PL3498281T3 PL17839530.7T PL17839530T PL3498281T3 PL 3498281 T3 PL3498281 T3 PL 3498281T3 PL 17839530 T PL17839530 T PL 17839530T PL 3498281 T3 PL3498281 T3 PL 3498281T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
substituted polycyclic
pyridone derivative
containing prodrug
Prior art date
Application number
PL17839530.7T
Other languages
English (en)
Inventor
Makoto Kawai
Kenji Tomita
Toshiyuki Akiyama
Azusa Okano
Masayoshi Miyagawa
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61020748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3498281(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Publication of PL3498281T3 publication Critical patent/PL3498281T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL17839530.7T 2016-08-10 2017-08-09 Podstawiona pochodna policyklicznego pirydonu i kompozycja farmaceutyczna zawierająca jej prolek PL3498281T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016157732 2016-08-10
PCT/JP2017/028923 WO2018030463A1 (ja) 2016-08-10 2017-08-09 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物

Publications (1)

Publication Number Publication Date
PL3498281T3 true PL3498281T3 (pl) 2024-11-12

Family

ID=61020748

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17839530.7T PL3498281T3 (pl) 2016-08-10 2017-08-09 Podstawiona pochodna policyklicznego pirydonu i kompozycja farmaceutyczna zawierająca jej prolek

Country Status (22)

Country Link
US (4) US10759814B2 (pl)
EP (2) EP4458348A3 (pl)
JP (2) JP6249434B1 (pl)
KR (3) KR20190014086A (pl)
CN (1) CN110494141A (pl)
AR (1) AR109315A1 (pl)
AU (2) AU2017310774B2 (pl)
CA (1) CA3033180C (pl)
CL (2) CL2019000325A1 (pl)
CR (1) CR20190123A (pl)
ES (1) ES2989872T3 (pl)
IL (1) IL264709B2 (pl)
MA (1) MA45939A (pl)
MX (2) MX390287B (pl)
PE (1) PE20190662A1 (pl)
PL (1) PL3498281T3 (pl)
RU (1) RU2727962C1 (pl)
SG (2) SG10201912212XA (pl)
TW (2) TWI663172B (pl)
UA (1) UA125218C2 (pl)
WO (1) WO2018030463A1 (pl)
ZA (2) ZA201900935B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230215T1 (hr) * 2015-04-28 2023-04-14 Shionogi & Co., Ltd. Supstituirani policiklički derivati piridona i njihov predlijek
SG10201911957QA (en) * 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
AU2017282305B2 (en) 2016-06-20 2021-06-10 Shionogi & Co., Ltd. Method for producing substituted polycyclic pyridone derivative and crystal of same
UA125218C2 (uk) * 2016-08-10 2022-02-02 Сіоногі Енд Ко., Лтд. Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
AU2018331172B2 (en) * 2017-09-18 2022-12-01 Sunshine Lake Pharma Co., Ltd. Influenza virus replication inhibitor and use thereof
WO2019070059A1 (ja) 2017-10-06 2019-04-11 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
CN110041327B (zh) * 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CA3088926A1 (en) * 2018-01-17 2019-07-25 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CN111303147B (zh) * 2018-12-12 2024-07-02 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
MX2020008959A (es) * 2018-02-28 2020-10-05 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
CN108440564B (zh) * 2018-04-11 2019-08-06 安帝康(无锡)生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药
WO2019208540A1 (ja) 2018-04-24 2019-10-31 塩野義製薬株式会社 安定性に優れた固形製剤
EP3785716A4 (en) * 2018-04-24 2022-03-02 Shionogi & Co., Ltd SOLID FORMULATION WITH EXCELLENT STABILITY
CN109956956B (zh) * 2018-05-15 2020-07-07 广东东阳光药业有限公司 一种并环吡啶酮化合物的制备方法
CN108558907B (zh) * 2018-06-01 2019-08-09 海化生命(厦门)科技有限公司 一种关键中间体2的制备方法
CN110317211B (zh) * 2018-07-27 2022-05-13 深圳市塔吉瑞生物医药有限公司 一种取代的多环性吡啶酮化合物及其前药
CN110872247A (zh) * 2018-08-29 2020-03-10 上海复星星泰医药科技有限公司 Xofluza含硫杂环化合物、其中间体及制备方法
WO2020058745A1 (en) * 2018-09-18 2020-03-26 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof
CN111377944A (zh) * 2018-12-25 2020-07-07 广东东阳光药业有限公司 Baloxavir marboxil晶型及其制备方法
EP3934758A1 (en) 2019-03-05 2022-01-12 Assia Chemical Industries Ltd Solid state forms of baloxavir marboxil
MX2021010884A (es) * 2019-03-12 2022-01-19 Shionogi & Co Tratamiento de la influenza con derivados de piridona policiclica sustituida y profarmacos de los mismos en un sujeto que tiene influenza y factor de riesgo de complicacion.
EP3714889A1 (en) 2019-03-29 2020-09-30 F. Hoffmann-La Roche AG Baloxavir for the prevention of transmission of influenza virus
WO2020205835A1 (en) * 2019-04-01 2020-10-08 Nikang Therapeutics, Inc. Fused polycyclic pyridone compounds as influenza virus replication inhibitors
CN111825699B (zh) * 2019-04-15 2023-02-21 上海复星星泰医药科技有限公司 含硫杂环化合物及其制备方法
RU2720305C1 (ru) * 2019-05-07 2020-04-28 Андрей Александрович Иващенко Замещенный 3,4,12,12а-тетрагидро-1Н-[1,4]оксазино[3,4-c]пиридо[2,1-f] [1,2,4]триазин-6,8-дион, фармацевтическая композиция, способы их получения и применения
CN111909174B (zh) * 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN110105372B (zh) * 2019-06-05 2022-05-10 南京焕然生物科技有限公司 一种r-7-(苄氧基)-四氢-1h-恶嗪并吡啶并-三嗪-6,8-二酮的制备方法
CN114907378A (zh) * 2019-07-11 2022-08-16 南京征祥医药有限公司 可用于治疗流感病毒感染的化合物
WO2021028024A1 (en) * 2019-08-13 2021-02-18 F. Hoffmann-La Roche Ag Improved dosage of baloxavir marboxil for pediatric patients
WO2021037956A1 (en) * 2019-08-27 2021-03-04 Atriva Therapeutics Gmbh Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
CN112552315B (zh) * 2019-09-26 2023-05-23 北京澳合药物研究院有限公司 一种巴洛沙韦玛波酯及其衍生物的纯化方法
WO2021057834A1 (zh) * 2019-09-27 2021-04-01 广东东阳光药业有限公司 一种酯化合物的晶型及其制备方法
CN112707862B (zh) * 2019-10-24 2022-09-27 广东东阳光药业有限公司 一种并环吡啶酮化合物的制备方法
WO2021093860A1 (zh) * 2019-11-13 2021-05-20 南京知和医药科技有限公司 取代的双三环化合物及其药物组合物和用途
CN118480041A (zh) * 2019-12-23 2024-08-13 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
CN112940009A (zh) * 2020-02-03 2021-06-11 南京知和医药科技有限公司 一种磺酸多环化合物及其药物组合物和用途
CN112876510A (zh) * 2020-02-10 2021-06-01 石家庄迪斯凯威医药科技有限公司 一种磷酸酯类多环化合物及其药物组合物和用途
CN111647005A (zh) * 2020-06-15 2020-09-11 安徽皓元药业有限公司 巴洛沙韦新晶型及其制备方法
CN111875619B (zh) * 2020-07-30 2021-06-25 深圳市新阳唯康科技有限公司 巴洛沙韦酯的晶型及其制备方法
CN111961064A (zh) * 2020-08-25 2020-11-20 石家庄龙泽制药股份有限公司 巴洛沙韦酯的新晶型及其制备方法和应用
CN112409379B (zh) * 2020-09-28 2023-07-28 长沙晶易医药科技股份有限公司 氘代的二氢二苯并硫杂卓化合物以及包含该化合物的药物组合物
CN112400801B (zh) * 2020-12-07 2022-07-22 天津医科大学第二医院 一种喉癌前病变动物模型及其构建方法和应用
AU2022205484B2 (en) * 2021-01-08 2024-12-05 Phaeno Therapeutics Co., Ltd. Pyridone multiple-membered ring derivatives and use thereof
TW202308646A (zh) * 2021-05-10 2023-03-01 大陸商南京征祥醫藥有限公司 治療流感化合物的晶型及應用
CN117343079B (zh) * 2022-07-05 2024-08-20 山东如至生物医药科技有限公司 一种新型抗流感病毒化合物及其药物组合物和用途
CN118496239A (zh) * 2023-04-14 2024-08-16 南京卡文迪许生物工程技术有限公司 一种酰乙酯多环化合物及其药物组合物和用途
CN116284048B (zh) * 2023-05-18 2023-08-15 长沙晶易医药科技股份有限公司 一种化合物及其制备方法、药物组合物和用途
CN116969970B (zh) * 2023-06-21 2026-02-03 山东大学 巴洛沙韦酯晶型b1及其制备方法
WO2025152855A1 (zh) * 2024-01-16 2025-07-24 上海翊石医药科技有限公司 用于治疗流感的化合物及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1830312A (en) * 1919-05-08 1931-11-03 Westinghouse Lamp Co Electric lamp
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CN100409844C (zh) * 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
WO2009042502A1 (en) 2007-09-27 2009-04-02 Air Cruisers Company Vessel escape slides and associated equipment
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) * 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US8987441B2 (en) * 2010-09-24 2015-03-24 Shionogi & Co., Ltd. Substituted polycyclic carbamoyl pyridone derivative prodrug
US8859290B2 (en) 2011-07-22 2014-10-14 Rutgers, The State University Of New Jersey Inhibitors of influenza endonuclease activity and tools for their discovery
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102600A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
HK1204987A1 (en) 2012-05-23 2015-12-11 Savira Pharmaceuticals Gmbh 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a]pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
CN104334563B (zh) 2012-05-23 2017-03-08 萨维拉制药有限公司 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途
CA2879245A1 (en) 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US9573938B2 (en) 2012-09-11 2017-02-21 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
WO2014074926A1 (en) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
HK1211288A1 (en) 2013-01-08 2016-05-20 Savira Pharmaceuticals Gmbh Naphthyridinone derivatives and their use in the treatment,amelioration or prevention of a viral disease
MX2015008288A (es) 2013-01-08 2016-06-02 Savira Pharmaceuticals Gmbh Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
AU2014204889A1 (en) 2013-01-08 2015-06-11 European Molecular Biology Laboratory Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
CN105722831B (zh) 2013-09-12 2019-08-06 艾丽奥斯生物制药有限公司 哒嗪酮化合物及其用途
AU2014318832B2 (en) 2013-09-12 2018-11-29 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
CN107001355A (zh) 2014-07-07 2017-08-01 萨维拉制药有限公司 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途
WO2016084922A1 (ja) * 2014-11-28 2016-06-02 塩野義製薬株式会社 1,2,4-トリアジン誘導体およびその医薬組成物
HRP20241039T1 (hr) 2015-04-28 2024-11-08 Shionogi & Co., Ltd Supstituirani derivat policikličkog piridona i njegov predlijek
HRP20230215T1 (hr) * 2015-04-28 2023-04-14 Shionogi & Co., Ltd. Supstituirani policiklički derivati piridona i njihov predlijek
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
SG10201911957QA (en) * 2015-12-15 2020-02-27 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6806413B2 (ja) 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
WO2017156194A1 (en) 2016-03-08 2017-09-14 The Regents Of The University Of California Compositions and methods for inhibiting influenza rna polymerase pa endonuclease
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
PL416447A1 (pl) 2016-03-10 2017-09-11 Międzynarodowy Instytut Biologii Molekularnej i Komórkowej w Warszawie Inhibitory nukleazy (kompleksu polimerazy) wirusa grypy
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AU2017282305B2 (en) 2016-06-20 2021-06-10 Shionogi & Co., Ltd. Method for producing substituted polycyclic pyridone derivative and crystal of same
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
UA125218C2 (uk) * 2016-08-10 2022-02-02 Сіоногі Енд Ко., Лтд. Фармацевтичні композиції, що містять заміщені поліциклічні піридонові похідні та їх проліки
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN108440564B (zh) 2018-04-11 2019-08-06 安帝康(无锡)生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药

Also Published As

Publication number Publication date
NZ750052A (en) 2024-08-30
JP2018048172A (ja) 2018-03-29
US20250257072A1 (en) 2025-08-14
US10759814B2 (en) 2020-09-01
EP3498281A1 (en) 2019-06-19
ZA201900935B (en) 2020-09-30
CA3033180C (en) 2022-05-31
MA45939A (fr) 2019-06-19
CA3033180A1 (en) 2018-02-15
JPWO2018030463A1 (ja) 2018-08-16
NZ791086A (en) 2025-08-29
AU2023202350A1 (en) 2023-05-11
KR20190014086A (ko) 2019-02-11
ES2989872T3 (es) 2024-11-28
UA125218C2 (uk) 2022-02-02
CL2020002032A1 (es) 2020-11-06
AU2017310774A1 (en) 2019-02-07
MX390287B (es) 2025-03-20
WO2018030463A1 (ja) 2018-02-15
JP6249434B1 (ja) 2017-12-20
KR20190018469A (ko) 2019-02-22
EP3498281C0 (en) 2024-08-28
EP3498281B1 (en) 2024-08-28
JP6267397B1 (ja) 2018-01-24
AR109315A1 (es) 2018-11-21
MX2019001640A (es) 2019-08-05
TWI711621B (zh) 2020-12-01
TW201808963A (zh) 2018-03-16
PE20190662A1 (es) 2019-05-08
US20200361958A1 (en) 2020-11-19
BR112019001911A2 (pt) 2019-05-07
US20220281890A1 (en) 2022-09-08
AU2023202350B2 (en) 2024-08-29
MX2021010629A (es) 2021-09-28
SG10201912212XA (en) 2020-02-27
ZA201908427B (en) 2021-05-26
AU2017310774A2 (en) 2019-03-14
IL264709B (en) 2022-10-01
US11306106B2 (en) 2022-04-19
SG11201900869QA (en) 2019-02-27
CR20190123A (es) 2019-04-30
TW201932113A (zh) 2019-08-16
EP3498281A4 (en) 2020-04-08
WO2018030463A9 (ja) 2019-01-24
AU2017310774B2 (en) 2023-01-19
CN110494141A (zh) 2019-11-22
EP4458348A2 (en) 2024-11-06
CL2019000325A1 (es) 2019-07-19
IL264709B2 (en) 2023-02-01
KR20190007517A (ko) 2019-01-22
IL264709A (pl) 2019-03-31
TWI663172B (zh) 2019-06-21
RU2727962C1 (ru) 2020-07-28
EP4458348A3 (en) 2025-01-29
US20190169206A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
ZA201908427B (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
IL282584A (en) History of quinoline and pharmaceutical preparations containing them
IL255295A0 (en) A modified polycyclic pyridone derivative and a hemane prodrug
IL265260B (en) pharmaceutical preparations
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
PL3426348T3 (pl) Pochodna 3-dezoksylowa i jej kompozycje farmaceutyczne
SI3290424T1 (sl) Substituirani policiklični piridonski derivati in njihovo predzdravilo
IL262654A (en) Pharmacy preparation
PL3412660T3 (pl) Pochodna sulfonamidowa i zawierająca ją kompozycja farmaceutyczna
IL265349A (en) Pharmaceutical composition
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
GB201615917D0 (en) Pharmaceutical composition
EP3345601A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
EP3342410A4 (en) PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF
GB201620519D0 (en) Pharmaceutical composition
GB201616088D0 (en) Pharmaceutical composition
GB201620517D0 (en) Pharmaceutical composition
GB201620516D0 (en) Pharmaceutical composition
GB201620515D0 (en) Pharmaceutical composition
GB201620513D0 (en) Pharmaceutical composition
GB201616093D0 (en) Pharmaceutical composition